Recently, the US FDA approved the Lithoplasty system for the treatment of vascular calcification plaques in patients with peripheral arterial disease (PAD), which was developed by Shockwave Medical, one of the pioneers dedicated to the treatment of calcified cardiovascular disease. It is expected to integrate Lithoplasty into the nursing pathway and improve it. The condition of patients with advanced cardiovascular disease. Peripheral arterial disease is a vascular disease in the peripheral region of the heart, also known as peripheral vascular disease. Symptoms of the disease are mainly characterized by limited blood flow reaching the body parts such as the legs and feet, causing severe pain and limited mobility in the limbs. In the most severe cases, surgery or even amputation may be required. The treatment of peripheral arterial disease depends on the severity of the disease, such as the doctor to develop a drug treatment plan according to the degree of disease deterioration, change the patient's lifestyle, or take a variety of programs such as angioplasty and stent implantation to open the blocked blood vessels. However, more than half of patients with this disease have moderate or severe calcification in their arteries, and it is often only possible to use the type of interventional device to successfully treat calcified arterial occlusion. It is understood that the Lithoplasty system is the first medical device to selectively target arterial calcification plaques in patients with cardiovascular disease. The device integrates two mature and powerful science technologies: the calcium interference power of sound waves (commonly known as "gravel", which is commonly used to treat patients with kidney stones) and a simple angioplasty balloon catheter device. Intermittent pulsed lithotripsy can loosen superficial and deep vascular calcium deposits while minimizing soft tissue damage, and then integrated balloon angioplasty can expand and block the blood flow at low pressure to restore blood flow. Lithoplasty system The US FDA's approval of the Lithoplasty system is based on a one-arm, two-stage, multi-center clinical study called DISRUPT PAD. The data show that DISRUPT PAD is consistently successful in all patient subgroups, and the marked increase rapidly Treats blood flow to blood vessels, causing minimal vascular damage. Novo admitted that many attempts to develop insulin tablets eventually failed. A successful tablet must not only withstand the acidic environment of the digestive tract, but also enter the bloodstream through the filtration of the intestinal wall. Soerensen called oral treatments "the largest research area in the company's history." His successor, Lars Fruergaard Joergensen, said investors should not expect major changes in strategy. If Novo can overcome these challenges, they will gain a sharp edge and resolve some of the pressures they face, said Kim Nielsen, a fund manager at Carnegie Asset Management in Copenhagen, who is also an investor in Novo. Novo has said it has experienced unprecedented competition in the largest market in the United States, and the company revealed last month that they lost a big contract for NovoLog. "Oral insulin is a major breakthrough," Nielsen said. “If anyone can successfully bring a good quality and guaranteed product to the market, it will be a big leap in the convenience of diabetes treatment.†In the forefront of convenience, France's Sanofi Inc. invested $248 million in Google's Verily Life Sciences LLC to develop a new technology that allows patients and their doctors to respond more quickly to blood sugar fluctuations and avoid diabetes Long-term complications such as heart disease and cancer caused by poor management. Prior to this, Google and Novartis had reached an agreement to develop invisible eyes that use microsensors to read glucose levels in tears. Yancheng Rongtai Labware Co.,Ltd , https://www.rongtailab.com
US FDA approves first cardiovascular disease sonication technology